| 論文作者 |
Le Blanc, K; Dazzi, F; English, K; Farge, D; Galipeau, J; Horwitz, EM; Kadri, N; Krampera, M; Lalu, MM; Nolta, J; Patel, NM; Shi, YF; Weiss, DJ; Viswanathan, S |
| 摘要 |
The December 2024 US Food and Drug Administration ( FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval. This approval will revive investment and enthusiasm in MSC products, further approvals in major markets, and will continue to foreshadow the long-predicted success of MSCs as a pharmaceutical. (c) 2025 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy. |
官方微信
